

U.S. Department of Justice

Washington, DC 20530

Exhibit A to Registration Statement**Pursuant to the Foreign Agents Registration Act of 1938, as amended**

INSTRUCTIONS. Furnish this exhibit for EACH foreign principal listed in an initial statement and for EACH additional foreign principal acquired subsequently. The filing of this document requires the payment of a filing fee as set forth in Rule (d)(1), 28 C.F.R. § 5.5(d)(1). Compliance is accomplished by filing an electronic Exhibit A form at <https://www.fara.gov>.

Privacy Act Statement. The filing of this document is required by the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, for the purposes of registration under the Act and public disclosure. Provision of the information requested is mandatory, and failure to provide this information is subject to the penalty and enforcement provisions established in Section 8 of the Act. Every registration statement, short form registration statement, supplemental statement, exhibit, amendment, copy of informational materials or other document or information filed with the Attorney General under this Act is a public record open to public examination, inspection and copying during the posted business hours of the FARA Unit in Washington, DC. Statements are also available online at the FARA Unit's webpage: <https://www.fara.gov>. One copy of every such document, other than informational materials, is automatically provided to the Secretary of State pursuant to Section 6(b) of the Act, and copies of any and all documents are routinely made available to other agencies, departments and Congress pursuant to Section 6(c) of the Act. The Attorney General also transmits a semi-annual report to Congress on the administration of the Act which lists the names of all agents registered under the Act and the foreign principals they represent. This report is available to the public in print and online at: <https://www.fara.gov>.

Public Reporting Burden. Public reporting burden for this collection of information is estimated to average .22 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Chief, FARA Unit, Counterintelligence and Export Control Section, National Security Division, U.S. Department of Justice, Washington, DC 20530; and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, DC 20503.

1. Name of Registrant

MEDSecurean, L.L.C.

2. Registration Number

7302

3. Primary Address of Registrant

74 Windy Hollow Court, Great Falls,, VA 22066

4. Name of Foreign Principal

Indian Pharmaceutical Alliance

5. Address of Foreign PrincipalA-205, Sangam Building 14B, SV Road, Santacruz West
Mumbai
INDIA 400 054**6. Country/Region Represented**

INDIA

7. Indicate whether the foreign principal is one of the following:☐ Government of a foreign country¹☐ Foreign political party☒ Foreign or domestic organization: If either, check one of the following:☐ Partnership☐ Committee☐ Corporation☐ Voluntary group☒ Association☐ Other (*specify*) _____☐ Individual-State nationality _____**8. If the foreign principal is a foreign government, state:**

a) Branch or agency represented by the registrant

b) Name and title of official(s) with whom registrant engages

¹ "Government of a foreign country," as defined in Section 1(e) of the Act, includes any person or group of persons exercising sovereign de facto or de jure political jurisdiction over any country, other than the United States, or over any part of such country, and includes any subdivision of any such group and any group or agency to which such sovereign de facto or de jure authority or functions are directly or indirectly delegated. Such term shall include any faction or body of insurgents within a country assuming to exercise governmental authority whether such faction or body of insurgents has or has not been recognized by the United States.

9. If the foreign principal is a foreign political party, state:

- a) Name and title of official(s) with whom registrant engages
- b) Aim, mission or objective of foreign political party

10. If the foreign principal is not a foreign government or a foreign political party:

a) State the nature of the business or activity of this foreign principal.

It is a trade association of Indian pharmaceutical companies, advocating for more business opportunities and better understanding of manufacturing compliance matters.

b) Is this foreign principal:

Supervised by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
Owned by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
Directed by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
Controlled by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
Financed by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
Subsidized in part by a foreign government, foreign political party, or other foreign principal	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>

11. Explain fully all items answered "Yes" in Item 10(b).

12. If the foreign principal is an organization and is not owned or controlled by a foreign government, foreign political party or other foreign principal, state who owns and controls it.

N/A

EXECUTION

In accordance with 28 U.S.C. § 1746, and subject to the penalties of 18 U.S.C. § 1001 and 22 U.S.C. § 618, the undersigned swears or affirms under penalty of perjury that he/she has read the information set forth in this statement filed pursuant to the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, that he/she is familiar with the contents thereof, and that such contents are in their entirety true and accurate to the best of his/her knowledge and belief.

Date

Printed Name

Signature

08/01/2023Kathleen Davidson Jaeger/s/Kathleen Davidson Jaeger

EXECUTION

In accordance with 28 U.S.C. § 1746, and subject to the penalties of 18 U.S.C. § 1001 and 22 U.S.C. § 618, the undersigned swears or affirms under penalty of perjury that he/she has read the information set forth in this statement filed pursuant to the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, that he/she is familiar with the contents thereof, and that such contents are in their entirety true and accurate to the best of his/her knowledge and belief.


Date

Printed Name

Signature

08/01/2023

Kathleen D. Jaeger



U.S. Department of Justice

Washington, DC 20530

Exhibit B to Registration Statement**Pursuant to the Foreign Agents Registration Act of 1938, as amended**

INSTRUCTIONS. A registrant must furnish as an Exhibit B copies of each written agreement and the terms and conditions of each oral agreement with his foreign principal, including all modifications of such agreements, or, where no contract exists, a full statement of all the circumstances by reason of which the registrant is acting as an agent of a foreign principal. Compliance is accomplished by filing an electronic Exhibit B form at <https://www.fara.gov>.

Privacy Act Statement. The filing of this document is required for the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, for the purposes of registration under the Act and public disclosure. Provision of the information requested is mandatory, and failure to provide the information is subject to the penalty and enforcement provisions established in Section 8 of the Act. Every registration statement, short form registration statement, supplemental statement, exhibit, amendment, copy of informational materials or other document or information filed with the Attorney General under this Act is a public record open to public examination, inspection and copying during the posted business hours of the FARA Unit in Washington, DC. Statements are also available online at the FARA Unit's webpage: <https://www.fara.gov>. One copy of every such document, other than informational materials, is automatically provided to the Secretary of State pursuant to Section 6(b) of the Act, and copies of any and all documents are routinely made available to other agencies, departments and Congress pursuant to Section 6(c) of the Act. The Attorney General also transmits a semi-annual report to Congress on the administration of the Act which lists the names of all agents registered under the Act and the foreign principals they represent. This report is available to the public in print and online at: <https://www.fara.gov>.

Public Reporting Burden. Public reporting burden for this collection of information is estimated to average .32 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Chief, FARA Unit, Counterintelligence and Export Control Section, National Security Division, U.S. Department of Justice, Washington, DC 20530; and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, DC 20503.

1. Name of Registrant
MEDSecurean, L.L.C.

2. Registration Number
7302

3. Name of Foreign Principal
Indian Pharmaceutical Alliance

Check Appropriate Box:

4. ☒ The agreement between the registrant and the above-named foreign principal is a formal written contract. If this box is checked, attach a copy of the contract to this exhibit.
5. ☐ There is no formal written contract between the registrant and the foreign principal. The agreement with the above-named foreign principal has resulted from an exchange of correspondence. If this box is checked, attach a copy of all pertinent correspondence, including a copy of any initial proposal which has been adopted by reference in such correspondence.
6. ☐ The agreement or understanding between the registrant and the foreign principal is the result of neither a formal written contract nor an exchange of correspondence between the parties. If this box is checked, give a complete description below of the terms and conditions of the oral agreement or understanding, its duration, the fees and expenses, if any, to be received.
7. What is the date of the contract or agreement with the foreign principal? 08/01/2023
8. Describe fully the nature and method of performance of the above indicated agreement or understanding.

See Appendix for Response

9. Describe fully the activities the registrant engages in or proposes to engage in on behalf of the above foreign principal.

Developing a strategy for more enhanced engagement with U.S. FDA, USTR, and State Department and others dealing with trade diversification efforts and manufacturing standards.

10. Will the activities on behalf of the above foreign principal include political activities as defined in Section 1(o) of the Act¹.

Yes ☒ No ☐

If yes, describe all such political activities indicating, among other things, the relations, interests or policies to be influenced together with the means to be employed to achieve this purpose. The response must include, but not be limited to, activities involving lobbying, promotion, perception management, public relations, economic development, and preparation and dissemination of informational materials.

See Appendix for Response

11. Prior to the date of registration² for this foreign principal has the registrant engaged in any registrable activities, such as political activities, for this foreign principal?

Yes ☐ No ☒

If yes, describe in full detail all such activities. The response should include, among other things, the relations, interests, and policies sought to be influenced and the means employed to achieve this purpose. If the registrant arranged, sponsored, or delivered speeches, lectures, social media, internet postings, or media broadcasts, give details as to dates, places of delivery, names of speakers, and subject matter. The response must also include, but not be limited to, activities involving lobbying, promotion, perception management, public relations, economic development, and preparation and dissemination of informational materials.

Set forth below a general description of the registrant's activities, including political activities.

Set forth below in the required detail the registrant's political activities.

Date	Contact	Method	Purpose
------	---------	--------	---------

-
12. During the period beginning 60 days prior to the obligation to register³ for this foreign principal, has the registrant received from the foreign principal, or from any other source, for or in the interests of the foreign principal, any contributions, income, money, or thing of value either as compensation, or for disbursement, or otherwise?

Yes ☐ No ☒

If yes, set forth below in the required detail an account of such monies or things of value.

Date Received	From Whom	Purpose	Amount/Thing of Value
---------------	-----------	---------	-----------------------

-
13. During the period beginning 60 days prior to the obligation to register⁴ for this foreign principal, has the registrant disbursed or expended monies, or disposed of anything of value other than money, in connection with activity on behalf of the foreign principal or transmitted monies to any such foreign principal?

Yes ☐ No ☒

If yes, set forth below in the required detail an account of such monies or things of value.

Date	Recipient	Purpose	Amount/Thing of Value
------	-----------	---------	-----------------------

¹ "Political activity," as defined in Section 1(o) of the Act, means any activity which the person engaging in believes will, or that the person intends to, in any way influence any agency or official of the Government of the United States or any section of the public within the United States with reference to formulating, adopting, or changing the domestic or foreign policies of the United States or with reference to the political or public interests, policies, or relations of a government of a foreign country or a foreign political party.

^{2,3,4} Pursuant to Section 2(a) of the Act, an agent must register within ten days of becoming an agent, and before acting as such.

EXECUTION

In accordance with 28 U.S.C. § 1746, and subject to the penalties of 18 U.S.C. § 1001 and 22 U.S.C. § 618, the undersigned swears or affirms under penalty of perjury that he/she has read the information set forth in this statement filed pursuant to the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, that he/she is familiar with the contents thereof, and that such contents are in their entirety true and accurate to the best of his/her knowledge and belief.

Date

Printed Name

Signature

08/01/2023Kathleen Davidson Jaeger/s/Kathleen Davidson Jaeger

EXECUTION

In accordance with 28 U.S.C. § 1746, and subject to the penalties of 18 U.S.C. § 1001 and 22 U.S.C. § 618, the undersigned swears or affirms under penalty of perjury that he/she has read the information set forth in this statement filed pursuant to the Foreign Agents Registration Act of 1938, as amended, 22 U.S.C. § 611 *et seq.*, that he/she is familiar with the contents thereof, and that such contents are in their entirety true and accurate to the best of his/her knowledge and belief.


Date

Printed Name

Signature

08/01/2023

Kathleen D. Jaeger



Appendix

Response to Item 8

Item 8: Describe fully the nature and method of performance of the above indicated agreement or understanding.

The scope of consulting services under the engagement include:

- a. Advance a closer relationship between India - U.S. to foster business, alliances, and investment opportunities for the Indian pharmaceutical industry. The scope of work aims to position the Indian pharmaceutical sector as a critical U.S. diversification supply solution and garner a seat at the table for IPA on significant security and healthcare-pharmaceutical policy discussions. This scope of work also includes IPA and MEDSECUREAN working collaboratively; and MEDSECUREAN closely monitoring the landscape that impacts the U.S. pharmaceutical and healthcare sector while conveying the Indian pharmaceutical industry's critical role in the U.S. healthcare system. This will require coordination with relevant stakeholders.
- b. Engagement with the United States Food and Drug Administration (U.S. FDA). India has largest number of U.S. FDA approved facilities outside U.S. The regulatory approvals, inspections and any changes thereof are vital for IPA companies. In this context, to work in close cooperation with U.S. FDA on matters of importance for IPA member companies and develop a goodwill campaign.
- c. National/International updates: Monthly Monitoring Report

Appendix

Response to Item 10

Item 10: Will the activities on behalf of the above foreign principal include political activities as defined in Section 1(o) of the Act. If yes, describe all such political activities indicating, among other things, the relations, interests or policies to be influenced together with the means to be employed to achieve this purpose. The response must include, but not be limited to, activities involving lobbying, promotion, perception management, public relations, economic development, and preparation and dissemination of informational materials.

Lobbying and influence activities will aim to drive policy changes with respect to diversification of generic pharmaceutical supply, which may include financial investments or incentives, or means to garner shared goals between India and U.S. and providing Indian pharmaceutical companies with more business opportunities in the United States. Activities will include preparing and disseminating materials, highlighting shared goals and potential solutions to diversify affordable medicine and related components and chemicals required for the production of these goods.

It also will include enhancing IPA's engagement with the US FDA with respect to foreign inspections and manufacturing innovation.

1 July 2023

Kathleen Jaeger
MEDSECUREAN, L.L.C
74 Windy Hollow Court, Great Falls, VA USA

TO WHOMSOEVER IT MAY CONCERN

Indian Pharmaceutical Alliance (hereinafter called as IPA) is pleased to offer MEDSECUREAN, L.L.C. through Ms Kathleen Jaeger (KJ), a consultant position on monthly retainerhip the details of which are in below paragraphs. The arrangement is for a period of 12 months from 1 August 2023 till 31 July 2024. We look forward to working with KJ to make a difference on issues affecting IPA member companies.

I. Scope of Services

The bilateral trade relationship between India and the United States (U.S.) has been consolidating in recent times. The COVID 19 pandemic and the changing geo-political landscape has highlighted the significance of close India-U.S. cooperation, particularly in the pharmaceutical sector. In this context, engaging with MEDSECUREAN, L.L.C to take forward the agenda of IPA members will be important. MEDSECUREAN, L.L.C will provide strategic advising and consultant services. The scope of services for this engagement includes the following areas:

- a. **Advance a closer relationship between India - U.S. to foster business, alliances, and investment opportunities for the Indian pharmaceutical industry.** The scope of work aims to position the Indian pharmaceutical sector as a critical U.S. diversification supply solution and garner a seat at the table for IPA on significant security and healthcare–pharmaceutical policy discussions. This scope of work also includes IPA and MEDSECUREAN working collaboratively; and MEDSECUREAN closely monitoring the landscape that impacts the U.S. pharmaceutical and healthcare sector while conveying the Indian pharmaceutical industry's critical role in the U.S. healthcare system. This will require coordination with relevant stakeholders.
- b. **Engagement with the United States Food and Drug Administration (U.S. FDA).** India has largest number of U.S. FDA approved facilities outside U.S. The regulatory approvals, inspections and any changes thereof are vital for IPA companies. In this context, to work in close cooperation with U.S. FDA on matters of importance for IPA member companies and develop a goodwill campaign.
- c. **National/International updates:** To prepare national/international updates for IPA, monitoring developments on matters in (a), (b) and any other matter relevant to IPA in the U.S. (one report per month).

II. Proposed Terms of the Agreement

Fee:

MEDSECUREAN, L.L.C professional services will be set at a monthly retainer fee of \$10,000 and will be paid on or around 28th day of every month. The parties do not expect any expenses; but if they occur, MEDSECUREAN will invoice IPA monthly and such expenses will be payable by IPA within thirty (30) days of receipt of invoice. Invoiced expenses will include a description of out-of-pocket travel and other expenses, and all available receipts. MEDSECUREAN will email expenses invoices to: Archana Jatkar via email (archana.jatkar@ipa-india.org)).

Term:

The term of the contract will be for a period of one year from 1 August 2023 to 31 July 2024. The IPA will pay the monthly retainer fee promptly upon signing of the Agreement and pay subsequent monthly retainer fees each month throughout the entire term of the contract upon submission of monthly invoice by MEDSECUREAN, L.L.C on or before 25th day of each month which will include a list of expenses incurred. All terms and conditions under this agreement shall be interpreted under the laws of the India.

- III. **Independent Contractor Status:** MEDSECUREAN will serve as an independent contractor with the authority to control and direct the performance of the details of the services to be provided. MEDSECUREAN representatives and employees will not hold themselves out as IPA employees. MEDSECUREAN further acknowledges and agrees that it is responsible for paying, according to applicable law, MEDSECUREAN's U.S. federal income taxes and filing under the Foreign Agents Registration Act.
- IV. **Personnel:** Kathleen Jaeger will be the primary contact for MEDSECUREAN for this engagement. However, IPA also agrees that MEDSECUREAN may involve other staff or consultant(s) in providing the scope of services within the organisation.
- V. **No Attorney-Client Relationship Established:** For the sake of clarity, the parties wish to reiterate that MEDSECUREAN does not provide legal services or advice.
- VI. **Conflicts of Interest:** By executing this Agreement, you acknowledge MEDSECUREAN's representation of other persons and entities on matters unrelated to the specific representation you have asked MEDSECUREAN to undertake on your behalf.
- VII. **Amendment:** Any amendment to this Agreement must be mutually agreed to in writing by both parties.

I hope this proposal is acceptable to you and look forward to working together.

Sincerely yours,

Indian Pharmaceutical Alliance (IPA)



Sudarshan Jain, Secretary General

Date: 1 July 2023

If the foregoing is acceptable, please sign below and return the executed copy to us.

AGREED AND ACCEPTED

Ms Kathleen Jaeger



Kathleen D. Jaeger

Date: July 15, 2023